HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has announced potential acquisition and financing agreements for $30 million in currently-operating interventional psychiatry clinics. Key points include:
1. A $30 million Term Sheet from a qualified lender for non-dilutive financing, expected to close within 60 days.
2. A non-binding Term Sheet with initial clinic partners generating over $10 million in annual revenue.
3. Projected annualized revenues of $100 million through continued acquisitions by mid-2025.
4. Focus on treating suicidal depression, treatment-resistant depression (TRD), and PTSD using ketamine therapy, TMS, and digital therapeutics.
5. Planned operations in the United States, France, and the United Kingdom.
HOPE Therapeutics, una consociata di NRx Pharmaceuticals (Nasdaq: NRXP), ha annunciato potenziali accordi di acquisizione e finanziamento per 30 milioni di dollari in centri di psichiatria interventistica attualmente operativi. I punti chiave includono:
1. Un Term Sheet di 30 milioni di dollari da un prestatore qualificato per finanziamenti non diluitivi, previsto in chiusura entro 60 giorni.
2. Un Term Sheet non vincolante con partner clinici iniziali che generano oltre 10 milioni di dollari di ricavi annuali.
3. Ricavi annualizzati previsti di 100 milioni di dollari attraverso continue acquisizioni entro metà 2025.
4. Focalizzazione sul trattamento della depressione suicidaria, della depressione resistente ai trattamenti (TRD) e del PTSD utilizzando terapie con ketamina, TMS e terapie digitali.
5. Operazioni pianificate negli Stati Uniti, in Francia e nel Regno Unito.
HOPE Therapeutics, una subsidiaria de NRx Pharmaceuticals (Nasdaq: NRXP), ha anunciado posibles acuerdos de adquisición y financiación por 30 millones de dólares en clínicas de psiquiatría interventionista actualmente en funcionamiento. Los puntos clave incluyen:
1. Un Term Sheet de 30 millones de dólares de un prestamista cualificado para financiamiento no dilutivo, previsto para cerrarse en 60 días.
2. Un Term Sheet no vinculante con socios clínicos iniciales que generan más de 10 millones de dólares en ingresos anuales.
3. Ingresos anuales proyectados de 100 millones de dólares a través de adquisiciones continuas para mediados de 2025.
4. Enfoque en el tratamiento de la depresión suicida, la depresión resistente al tratamiento (TRD) y el PTSD utilizando terapia con ketamina, TMS y terapias digitales.
5. Operaciones planificadas en los Estados Unidos, Francia y el Reino Unido.
HOPE Therapeutics는 NRx Pharmaceuticals (Nasdaq: NRXP)의 자회사로, 현재 운영 중인 개입 정신의학 클리닉에 대해 3천만 달러의 잠재적 인수 및 금융 계약을 발표했습니다. 주요 사항은 다음과 같습니다:
1. 비희석 자금을 위한 자격 있는 대출 기관으로부터 3천만 달러의 조건서를 받아, 60일 이내에 마감될 예정입니다.
2. 연간 1천만 달러 이상의 수익을 창출하는 초기 클리닉 파트너와의 비구속 조건서.
3. 2025년 중반까지 지속적인 인수를 통해 예상 연간 수익 1억 달러.
4. 케타민 치료, TMS 및 디지털 치료법을 사용하여 자살을 시도한 우울증, 치료 저항성 우울증(TRD) 및 PTSD 치료에 초점을 맞추고 있습니다.
5. 미국, 프랑스 및 영국에서 운영 예정입니다.
HOPE Therapeutics, une filiale de NRx Pharmaceuticals (Nasdaq: NRXP), a annoncé des accords potentiels d'acquisition et de financement pour 30 millions de dollars dans des cliniques de psychiatrie interventionnelle actuellement en fonctionnement. Les points clés incluent :
1. Un Term Sheet de 30 millions de dollars d'un prêteur qualifié pour un financement non dilutif, prévu pour se clôturer dans 60 jours.
2. Un Term Sheet non contraignant avec des partenaires cliniques initiaux générant plus de 10 millions de dollars de revenus annuels.
3. Des revenus annualisés projetés de 100 millions de dollars grâce à des acquisitions continues d'ici la mi-2025.
4. Concentration sur le traitement de la dépression suicidaire, de la dépression résistante aux traitements (TRD) et du PTSD en utilisant la thérapie par kétamine, la TMS et les thérapies numériques.
5. Opérations prévues aux États-Unis, en France et au Royaume-Uni.
HOPE Therapeutics, eine Tochtergesellschaft von NRx Pharmaceuticals (Nasdaq: NRXP), hat potenzielle Übernahme- und Finanzierungsvereinbarungen in Höhe von 30 Millionen US-Dollar für derzeit betriebene intervenierende psychiatrische Kliniken bekannt gegeben. Zu den wichtigsten Punkten gehören:
1. Ein Term Sheet über 30 Millionen US-Dollar von einem qualifizierten Kreditgeber für nicht verwässernde Finanzierung, das innerhalb von 60 Tagen abgeschlossen werden soll.
2. Ein unverbindliches Term Sheet mit anfänglichen Klinikpartnern, die mehr als 10 Millionen Dollar Jahresumsatz generieren.
3. Voraussichtliche annualisierte Einnahmen von 100 Millionen US-Dollar durch fortlaufende Übernahmen bis Mitte 2025.
4. Fokus auf die Behandlung von suizidaler Depression, behandlungsresistenter Depression (TRD) und PTSD mit Kehtamintherapie, TMS und digitalen Therapeutika.
5. Geplante Aktivitäten in den USA, Frankreich und dem Vereinigten Königreich.
- $30 million non-dilutive financing Term Sheet for clinic acquisitions
- Non-binding Term Sheet with initial clinic partners generating over $10 million in annual revenue
- Projected annualized revenues of $100 million through acquisitions by mid-2025
- Expansion into multiple countries: US, France, and UK
- Diversified treatment approach combining pharmaceutical therapy, FDA-approved technologies, and digital therapeutics
- Term Sheets are non-binding, indicating potential uncertainty in deal completion
- Rapid expansion through acquisitions may pose integration challenges
- Dependence on successful execution of acquisition strategy for revenue growth
Insights
This announcement signals a significant strategic move for HOPE Therapeutics and NRx Pharmaceuticals. The $30 million non-dilutive financing for clinic acquisitions is a smart capital allocation strategy, allowing expansion without immediate shareholder dilution. The projected $100 million annualized revenue by mid-2025 through acquisitions is ambitious but could be achievable given the
However, investors should note that these are non-binding agreements. The success of this strategy hinges on deal closures and effective integration of acquired clinics. The mental health market, particularly for interventional psychiatry, shows strong growth potential, but regulatory risks and competition from established players could pose challenges. The company's focus on a unified, science-based approach could be a differentiator in this fragmented market.
HOPE's strategy to create a unified platform for treating suicidal depression, TRD and PTSD is innovative and addresses a critical need in mental health care. The combination of pharmaceutical therapy, FDA-approved technologies like TMS, digital therapeutics and access to clinical trials could potentially improve patient outcomes. However, the effectiveness of this integrated approach remains to be proven at scale.
The focus on ketamine therapy is noteworthy, given its emerging role in treating resistant depression. But it's important to monitor long-term efficacy and safety data. The company's plan to operate in multiple countries (US, France, UK) could accelerate data collection and best practices sharing, potentially leading to improved treatment protocols. This expansion could also facilitate faster enrollment in clinical trials for new treatments, a significant advantage in the competitive psychopharmacology field.
$30 million - Executed Non-Binding Term Sheet with initial clinic partners generating annual revenue of over
$10 million - Company projects annualized revenues of
$100 million - Additional information to be presented at upcoming HC Wainwright Annual Global Investment Conference in
New York , September 9-11, 2024
The non-dilutive acquisition funding announced today is in addition to the over
Ketamine is increasingly used to treat suicidal depression, treatment resistant depression (TRD) and Post Traumatic Stress Disorder (PTSD). Until now there has been no unified entity organized around delivering consistent outpatient care for suicidal depression, TRD and PTSD that combines pharmaceutical therapy, FDA approved and proven medical technologies such as Transcranial Magnetic Stimulation (TMS), digital therapeutics and access to clinical trial protocols for the newest potential treatments, delivered by properly licensed medical professionals to optimize care of people with these conditions. Collectively, these conditions represent a crisis that results in the death of someone around the globe every minute. HOPE aims to bring a unified, patient-centric and science-based approach to the care of patients and their families.
"HOPE is dedicated to providing an accessible platform to help caregivers address the critical needs of those suffering from suicidal thoughts, TRD, PTSD and related challenges. We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care and demonstrate best-practices for mental health professionals around the world," said Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "These clinics, and others under review, are planned to provide the foundation for a network generating revenue of approximately
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-potential-acquisition-and-financing-agreements-for-30-million-in-currently-operating-interventional-psychiatry-clinics-302230157.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the value of the financing agreement announced by HOPE Therapeutics (NRXP) for clinic acquisitions?
What are the projected revenues for HOPE Therapeutics (NRXP) by mid-2025?
Which countries does HOPE Therapeutics (NRXP) plan to operate in?
What medical conditions does HOPE Therapeutics (NRXP) focus on treating?
What treatment methods does HOPE Therapeutics (NRXP) plan to use in its clinics?
